Oric Pharmaceuticals Stock Current Liabilities
| ORIC Stock | USD 9.87 0.28 2.92% |
Oric Pharmaceuticals fundamentals help investors to digest information that contributes to Oric Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Oric Stock. The fundamental analysis module provides a way to measure Oric Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oric Pharmaceuticals stock.
As of November 25, 2024, Total Current Liabilities is expected to decline to about 11.1 M. In addition to that, Non Current Liabilities Total is expected to decline to about 7.1 M. Oric | Current Liabilities |
Oric Pharmaceuticals Company Current Liabilities Analysis
Oric Pharmaceuticals' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Oric Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Oric Pharmaceuticals is extremely important. It helps to project a fair market value of Oric Stock properly, considering its historical fundamentals such as Current Liabilities. Since Oric Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oric Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oric Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Oric Current Liabilities Historical Pattern
Today, most investors in Oric Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Oric Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Oric Pharmaceuticals current liabilities as a starting point in their analysis.
Oric Pharmaceuticals Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Oric Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Oric Pharmaceuticals has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Oric Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oric Pharmaceuticals' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oric Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Oric Pharmaceuticals by comparing valuation metrics of similar companies.Oric Pharmaceuticals is currently under evaluation in current liabilities category among its peers.
Oric Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Oric Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Oric Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Oric Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 407.49 M | ||||
| Shares Outstanding | 70.57 M | ||||
| Shares Owned By Insiders | 9.12 % | ||||
| Shares Owned By Institutions | 90.88 % | ||||
| Number Of Shares Shorted | 11.65 M | ||||
| Price To Book | 2.47 X | ||||
| EBITDA | (109.75 M) | ||||
| Net Income | (100.7 M) | ||||
| Cash And Equivalents | 227.06 M | ||||
| Cash Per Share | 5.74 X | ||||
| Total Debt | 10.21 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 18.72 X | ||||
| Book Value Per Share | 3.88 X | ||||
| Cash Flow From Operations | (85.69 M) | ||||
| Short Ratio | 29.34 X | ||||
| Earnings Per Share | (1.82) X | ||||
| Target Price | 18.73 | ||||
| Number Of Employees | 112 | ||||
| Beta | 1.12 | ||||
| Market Capitalization | 676.74 M | ||||
| Total Asset | 252.01 M | ||||
| Retained Earnings | (434.93 M) | ||||
| Working Capital | 192.14 M | ||||
| Net Asset | 252.01 M |
About Oric Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oric Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oric Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oric Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Oric Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oric Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oric Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oric Pharmaceuticals Stock:Check out Oric Pharmaceuticals Piotroski F Score and Oric Pharmaceuticals Altman Z Score analysis. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.82) | Return On Assets (0.29) | Return On Equity (0.46) |
The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oric Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.